Company Overview
Company Type: Private Company
Website: www.cplltd.com
Number of Employees: 300
Year Founded: 1991
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Contract Pharmaceuticals Limited, a contract development and manufacturing organization, engages in the development, manufacturing, packaging, and testing of non-sterile liquid and semi-solid pharmaceutical and regulated OTC products. The company offers product development services that include formulation development and analytical testing services; and commercial manufacturing services, including manufacturing, filling and packaging, and testing. Its products include non-sterile liquids, such as suspensions, solutions, and nasal and topical sprays; and semi-solids, including lotions, creams, ointments, and gels. Contract Pharmaceuticals Limited was founded in 1991 and is headquartered in Mississauga, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
 136.1
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 300
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Paige, Ken
Chief Executive Officer and Director
Vieno, Marcel 
Vice President of Finance
De Rango, Erika
Vice President of Operations
Sahai, Jan
Vice President of Business Development

Key Board Members
Name
Title
Paige, Ken
Chief Executive Officer and Director


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
7600 Danbro Crescent | Mississauga, ON | L5N 6L6 | Canada
Phone: 905 821 7600   Fax: 905 821 7601


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Bristol-Myers Squibb Company, Forest Avenue Plant
As of October 1, 2005, Bristol-Myers Squibb Company, Forest Avenue Plant was acquired by Contract Pharmaceuticals Limited.

United States and Canada
-
-
-
-
Bristol-Myers Squibb, Buffalo Plant
As of August 31, 2005, Buffalo Plant of Bristol-Myers Squibb was acquired by Contract Pharmaceuticals Limited. Bristol-Myers Squibb, Buffalo Plant manufactures over-the-counter and prescription pharmaceutical products. The asset offers products such as Keri lotion and related creams and ointments. Bristol-Myers Squibb, Buffalo Plant was formerly known as Westwood Pharmaceuticals. The asset is based in Buffalo, New York.

United States and Canada
Pharmaceuticals
-
-
-
Innopharm Inc.
Innopharm Inc., a contract services laboratory, serves pharmaceutical and biotechnology industries in Canada. It offers analytical lab, analytical validation studies, chemical analysis, dissolution testing, methods validation, stability, and wet chemical analysis services. The company was founded in 1999 and is based in Markham, Canada. Innopharm Inc. operates as a subsidiary of Contract Pharmaceuticals Limited.

United States and Canada
Pharmaceuticals
-
-
-
Contract Pharmaceuticals Limited Niagara
Contract Pharmaceuticals Limited Niagara manufactures pharmaceutical products. The company was founded in 2005 and is based in Buffalo, New York. Contract Pharmaceuticals Limited Niagara operates as a subsidiary of Contract Pharmaceuticals Limited.

United States and Canada
Pharmaceuticals
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-30-2005
Aug-31-2005
Merger/Acquisition
Buyer
Bristol-Myers Squibb, Buffalo Plant
Contract Pharmaceuticals Limited
Bristol-Myers Squibb Sarl
-
Jun-30-2005
Oct-1-2005
Merger/Acquisition
Buyer
Bristol-Myers Squibb Company, Forest Avenue Plant
Contract Pharmaceuticals Limited
Bristol-Myers Squibb Company (NYSE:BMY)
-
Jun-4-2003
Jun-4-2003
Merger/Acquisition
Buyer
Innopharm Inc.
Contract Pharmaceuticals Limited

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Feb-25-2021
Client Announcements
OptiNose, Inc. Enters into Amendment No. 1 to that Certain Manufacture and Supply Agreement with Contract Pharmaceuticals Limited
Apr-15-2020
Product-Related Announcements
Contract Pharmaceuticals Limited Launches Production of Hand-Sanitizer to Meet Critical Shortages
Jun-17-2011
Discontinued Operations/Downsizings
Contract Pharmaceuticals Limited Begins Second Phase of Terminations
Feb-07-2011
Discontinued Operations/Downsizings
Contract Pharmaceuticals Limited Files Warn Layoff Notice for the Shutdown of its Blowmolding Department at the Forest Avenue Plant
May-21-2010
Discontinued Operations/Downsizings
Contract Pharmaceuticals Limited Plans to Close its Buffalo Plant at the End of 2011


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 18, 2023 02:40 AM
Contract Pharmaceuticals Limited
Contract Pharmaceuticals Ltd
Reports
24
GlobalData

Sep 16, 2022 06:48 AM
Contract Pharmaceuticals Limited
Contract Pharmaceuticals Ltd
Reports
23
GlobalData

Jun 16, 2022 11:40 PM
Contract Pharmaceuticals Limited
Contract Pharmaceuticals Ltd
Reports
23
GlobalData

Mar 11, 2022 01:45 AM
Contract Pharmaceuticals Limited
Contract Pharmaceuticals Ltd
Reports
22
GlobalData

Dec 14, 2021 02:30 AM
Contract Pharmaceuticals Limited
Contract Pharmaceuticals Ltd
Reports
20
GlobalData

Sep 15, 2021 02:57 AM
Contract Pharmaceuticals Limited
Contract Pharmaceuticals Ltd
Reports
16
GlobalData

Jun 14, 2021 09:19 AM
Contract Pharmaceuticals Limited
Contract Pharmaceuticals Ltd
Reports
15
GlobalData

Dec 10, 2020 10:46 PM
Contract Pharmaceuticals Limited
Contract Pharmaceuticals Ltd
Reports
15
GlobalData

Sep 16, 2020 01:11 AM
Contract Pharmaceuticals Limited
Contract Pharmaceuticals Ltd
Reports
15
GlobalData

Jun 15, 2020 10:39 PM
Contract Pharmaceuticals Limited
Contract Pharmaceuticals Ltd
Reports
15


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Paige, Ken
Chief Executive Officer and Director
905 821 7600
905 821 7601
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Paige, Ken
Chief Executive Officer and Director
905 821 7600
905 821 7601
-
Vieno, Marcel 
Vice President of Finance
905 821 7600
905 821 7601

De Rango, Erika
Vice President of Operations
905 821 7600
905 821 7601
-
Sahai, Jan
Vice President of Business Development
905 821 7600
905 821 7601
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
